Skip to main content
UploadLanguage (EN)Support
BusinessMobileSocial MediaMarketingTechnologyArt & PhotosCareerDesignEducationPresentations & Public SpeakingGovernment & NonprofitHealthcareInternetLawLeadership & ManagementAutomotiveEngineeringSoftwareRecruiting & HRRetailSalesServicesScienceSmall Business & EntrepreneurshipFoodEnvironmentEconomy & FinanceData & AnalyticsInvestor RelationsSportsSpiritualNews & PoliticsTravelSelf ImprovementReal EstateEntertainment & HumorHealth & MedicineDevices & HardwareLifestyle
accenture, profile picture
Uploaded byaccenture
PDF, PPTX35,539 views

New Science: Pharma's new growth machine

The document discusses the emergence of a new growth engine in the biopharma industry, referred to as 'new science,' in response to compressive disruption impacting the sector. Key indicators highlight declining investor confidence, decreasing tenure of market-leading treatments, and lower pipeline replacement ratios, which are expected to result in a significant revenue drop. New science, which is anticipated to contribute to 54% of industry revenue from 2017 to 2022, demonstrates a higher likelihood of regulatory success and demands increased investment in technology and data integration.

Technology◦
Related topics:
Life Sciences• Pharmaceutical Industry• Patient Outcomes•
Download as PDF, PPTX
NEW SCIENCE Biopharma’s New Growth Machine Accenture LifeSciences Patient Inspired. Outcomes Driven.
2 The Biopharma industry is facing compressive disruption, But a new growth engine is emerging that will drive the majority of revenue through 2022. We call it New Science.
3 WHAT IS COMPRESSIVE DISRUPTION? Many asset-heavy organizations are experiencing a gradual and dangerous “compressive disruption” when a series of innovations, macroeconomic factors and other changes combine to squeeze profits over time.
BIOPHARMA’S COMPRESSIVE DISRUPTION DECLINES IN: Three key indicators in Biopharma Investor confidence in future earnings Tenure of marketing leading treatments Pipeline replacement ratios 01 02 03
5 Investor confidence in future earnings is declining. Future Value as a percentage of Total Enterprise Value has dropped for three years in a row, from 42% in 2015 to 28% in 2018. BIOPHARMA’S COMPRESSIVE DISRUPTION 01 Sources: Capital IQ. Accenture Research Analysis. Calculations are the aggregated values for the pharmaceutical segment. Accenture High Performance Business Analysis 2018. Pharmaceutical & Biotechnology relative performance analysis of indicators including, growth profitability, and value indicators as reported by the market and monitored over 10 years. The HPB study identifies which companies are top performers within their industry and what distinguished them from their international peers
6 Tenure of market leading treatments is declining. Average tenure for a market leading treatment in a therapeutic area has dropped from 10.5 years in 2001 to 5.1 years in 2017. BIOPHARMA’S COMPRESSIVE DISRUPTION 02 Source: Accenture analysis, data provided by Evaluate Pharma
7 BIOPHARMA’S COMPRESSIVE DISRUPTION 50% decline expected from 2012 thru 2022. More specialized treatments coming to market that treat smaller patient populations generating lower revenues. Pipeline replacement ratios are declining.03 Source: Accenture analysis, data provided by Evaluate Pharma
NEW SCIENCE INVOLVES: A new mechanism, modality, indication or health technology that has been identified by the FDA or other regulatory entity as having met an unmet need, exceeding standard of care Often has a technology companion Can be the technology alone WHAT IS NEW SCIENCE?
9 NEW SCIENCE WILL DRIVE THE MAJORITY OF INDUSTRY GROWTH New Science is expected to drive 54% of industry revenue from 2017-2022. Source: Accenture Research. Capital IQ.
10 NEW SCIENCE IS DRIVING EXCEPTIONAL GROWTHACROSS MULTIPLE THERAPEUTIC AREAS Source: Accenture analysis, data provided by Evaluate Pharma
11 NEW SCIENCE IS MORE LIKELY TO REACH AND PASS REGULATORY APPROVAL New Science has a 50% higher probability of Technical and Regulatory Success (PTRS) compared to other NMEs and NBE’s. Source: Accenture analysis, data provided by Informa Pharmapremia
12 LEADERS IN NEW SCIENCE ARE INVESTING 6-7 X’S AS MUCH IN DIGITAL, DATA AND GENOMICS Investments represent convergence of science and technology rising to meet demand for proof of improved outcomes. Source: Accenture analysis
13 TECHNOLOGY IS FAST BECOMING PART OF TREATMENT in some cases, the entire treatment.
14
18 RESEARCH METHODOLOGY Accenture Research defines a segment of science as new across three dimensions. Based on a global product level analysis of 4000 unique products of a total validated data base of 60,000 unique products as updated December 15, 2018. This New Science Growth Assessment was undertaken to better understand growth/risk levers for products, companies and therapeutic areas and to define an actionable category of interest and further evaluation. Copyright © 2019 Accenture. All rights reserved.